CLINICAL_TRIALS
trial_result
· 2016-01-06
Clinical Trial Update: Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) [Phase 2]
Summary
A Phase 2a trial evaluating arsenic trioxide for systemic lupus erythematosus has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nantes University Hospital | Conditions: Systemic Lupus | Phase 2 | Status: TERMINATED